The graph on the next tab is what we at MD Scientific, LLC call our Risk-Benefit or "Safety versus Performance" graph. The slide looks at studies involving tight glycemic control and the use of IV insulin in a critical care setting. The data on the slide shows the performance of the control and active treatment groups from the major clinical trials in peer reviewed literature beginning with Grete Van den Berghe's study from the New England Journal of Medicine in 2001. The horizontal, or "X" axis shows the mean of all the blood glucose readings from the trials. The lower the BG to normal, the higher the benefit, or performance. The vertical, or "Y" axis, shows the rate of hypoglycemia as the percent of patients. As the rate of hypoglycemia rises, the risk increases and the safety decreases.
What is striking is that in every case, when you compare the control group with the active treatment group, the rate of hypoglycemia rises.
The exception to this trend is the control seen with the EndoTool® Glucose Management System software. With over 200,000 readings in over 5000 patients, the average BG with EndoTool® is 118 mg/dL, with a rate of hypoglycemia of just 2.0% of patients. This data comes from 8 community hospitals and one major academic hospital. The patients are from four cardiac surgery recover units, one Level 1 trauma unit, and several surgical, medical and mixed ICU's.
If your hospital is not producing these types of results, contact your MD Scientific Applications Representative at (704) 323-1300, or info@mdsci.com for more information.
|
